U.S. markets close in 6 hours 14 minutes
  • S&P 500

    3,855.84
    -14.45 (-0.37%)
     
  • Dow 30

    31,419.53
    +28.01 (+0.09%)
     
  • Nasdaq

    13,251.59
    -107.20 (-0.80%)
     
  • Russell 2000

    2,238.83
    +7.32 (+0.33%)
     
  • Crude Oil

    60.83
    +1.08 (+1.81%)
     
  • Gold

    1,711.00
    -22.60 (-1.30%)
     
  • Silver

    26.23
    -0.65 (-2.43%)
     
  • EUR/USD

    1.2055
    -0.0032 (-0.27%)
     
  • 10-Yr Bond

    1.4740
    +0.0590 (+4.17%)
     
  • GBP/USD

    1.3951
    -0.0005 (-0.04%)
     
  • USD/JPY

    107.0620
    +0.3520 (+0.33%)
     
  • BTC-USD

    50,847.44
    +1,969.44 (+4.03%)
     
  • CMC Crypto 200

    1,015.71
    +27.62 (+2.80%)
     
  • FTSE 100

    6,640.65
    +26.90 (+0.41%)
     
  • Nikkei 225

    29,559.10
    +150.93 (+0.51%)
     

Aclaris Therapeutics to Participate in Upcoming Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
Aclaris Therapeutics, Inc.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

WAYNE, Pa., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will present a company overview at the following upcoming virtual investor conferences:

  • H.C. Wainwright Global Life Sciences Conference. Tuesday, March 9, 2021 at 7:00 a.m. ET. Management will be available March 9th and 10th throughout the day for virtual one-on-one meetings.

  • Oppenheimer 31st Annual Healthcare Conference. Tuesday, March 16, 2021 at 10:00 a.m. ET. Management will be available March 16th throughout the day for virtual one-on-one meetings.

A live audio webcast of each presentation may be accessed through the “Events” page of the “Investors” section of Aclaris’ website, www.aclaristx.com. Each webcast will be archived for at least 30 days on the Aclaris website.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.

Aclaris Contact

investors@aclaristx.com